Trexquant Investment LP Purchases 5,770 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Trexquant Investment LP increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 41.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,806 shares of the biotechnology company’s stock after acquiring an additional 5,770 shares during the period. Trexquant Investment LP’s holdings in United Therapeutics were worth $4,355,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of UTHR. International Assets Investment Management LLC increased its holdings in United Therapeutics by 13,769.2% in the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after purchasing an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale increased its stake in shares of United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after buying an additional 33,338 shares during the period. Nordea Investment Management AB raised its position in shares of United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after acquiring an additional 23,532 shares during the last quarter. BNP Paribas Financial Markets increased its position in United Therapeutics by 90.3% during the 4th quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after purchasing an additional 26,325 shares during the period. Finally, Duality Advisers LP raised its holdings in United Therapeutics by 56.1% during the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after purchasing an additional 5,622 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on UTHR. HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. JPMorgan Chase & Co. raised their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday. Wedbush reissued an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. Wells Fargo & Company increased their price target on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. Finally, The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $309.44.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $276.44 on Thursday. The company has a market cap of $12.26 billion, a P/E ratio of 13.07, a PEG ratio of 4.17 and a beta of 0.54. The company has a fifty day simple moving average of $245.78 and a 200 day simple moving average of $233.38. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $279.98. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.86 EPS. Sell-side analysts predict that United Therapeutics Co. will post 24.2 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Martine A. Rothblatt sold 1,468 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $275.85, for a total transaction of $404,947.80. Following the transaction, the director now directly owns 130 shares of the company’s stock, valued at $35,860.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,756.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Martine A. Rothblatt sold 1,468 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $275.85, for a total transaction of $404,947.80. Following the completion of the sale, the director now directly owns 130 shares in the company, valued at approximately $35,860.50. The disclosure for this sale can be found here. Insiders have sold 155,208 shares of company stock worth $37,436,641 over the last 90 days. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.